Evidence map›Paper›PMID 30267779›Full record

ArticleHuman pathology2019

Expression pattern of androgen receptor and AR-V7 in androgen-deprivation therapy-naïve salivary duct carcinomas.

Richard K Yang, Pei Zhao, Changxue Lu, Jun Luo, Rong Hu

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Phase II Study of Enzalutamide for Patients With Androgen Receptor-Positive Salivary Gland Cancers (Alliance A091404).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022
    Trial
  4. Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor-Expressing Salivary Gland Cancer: A Phase II Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021
    Trial
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Richard K YangDepartment of Pathology and Laboratory Medicine, University of Wisconsin, Madison, WI 53792, USA.
Pei ZhaoDepartment of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University, Baltimore, MD 21287, USA.
Changxue LuDepartment of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University, Baltimore, MD 21287, USA.
Jun LuoDepartment of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University, Baltimore, MD 21287, USA.
Rong HuDepartment of Pathology and Laboratory Medicine, University of Wisconsin, Madison, WI 53792, USA. Electronic address: rhu@uwhealth.org.
Johns Hopkins University · USUniversity of Wisconsin–Madison · US

Funding

Project 4: Role of Receptor Tyrosine Kinase AXL in HNSCC Therapy ResistanceP50DE026787 · NIDCR · UNIVERSITY OF WISCONSIN-MADISON · PI YU, MENGGANG · 2016 to 2020
$10.8M
NIDCR NIH HHS P50 DE026787
6 · The paper itself

Abstract

Androgen-deprivation therapy has been used to treat salivary duct carcinoma (SDC). The androgen receptor splice variant-7 (AR-V7) has been detected in castration-resistant prostate cancer and implicated in resistance to androgen receptor (AR)-targeted therapies. Given the potential role of AR/AR-V7 in SDC treatment, this study focuses on AR/AR-V7 expression in SDC specimens collected before androgen-deprivation therapy. RNA in situ hybridization (ISH) and immunohistochemistry (IHC) to detect total AR and AR-V7 were performed on formalin-fixed, paraffin-embedded SDC specimens from 23 patients. Full-length AR and AR-V7 transcripts were quantified in a subset of tumors by reverse-transcription polymerase chain reaction. Twenty SDCs were positive for total AR by ISH and IHC. Among AR-positive SDCs, 70% (14/20) were positive for AR-V7 messenger RNA by ISH, whereas 15% (3/20) were positive for AR-V7 protein by IHC. The 3 SDCs that expressed the highest levels of AR-V7 were all from female patients; one of them expressed a significant amount of AR-V7 and barely detectable full-length AR transcripts by reverse-transcription polymerase chain reaction. IHC expression of Forkhead box protein A1, prostate-specific antigen, prostatic acid phosphatase, and NKX3.1 was observed in some SDCs regardless of patient sex. Five SDCs demonstrated strong human epidermal growth factor receptor 2 expression. We conclude that treatment-naïve SDCs may express AR-V7 at levels comparable to or even exceeding the levels detected in castration-resistant prostate cancer. Our data support the feasibility to incorporate AR-V7 assessment via ISH and/or IHC in the ongoing clinical trials evaluating the therapeutic benefit of AR-targeted therapies in SDC patients.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, DuctalFemaleHumansMaleMiddle AgedProtein IsoformsReceptors, AndrogenSalivary DuctsSalivary Gland NeoplasmsBiomarkers, TumorProtein IsoformsReceptors, AndrogenAndrogen-deprivation therapyAndrogen receptorAR-V7ImmunohistochemistryRNA in situ hybridizationSalivary duct carcinoma

Identifiers

PMID30267779
PMCPMC7098468
OpenAlexW2892781089

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.